BSE Live
Apr 02, 16:01Prev. Close
20.85
Open Price
19.85
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Dec 27, 11:22Prev. Close
-
Open Price
-
Bid Price (Qty.)
- (0)
Offer Price (Qty.)
- (0)
| Balance Sheet of Brawn Biotech (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| EQUITIES AND LIABILITIES | ||||||
| SHAREHOLDER'S FUNDS | ||||||
| Equity Share Capital | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | |
| Total Share Capital | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | |
| Reserves and Surplus | 0.36 | 2.06 | 3.31 | 4.22 | 5.79 | |
| Total Reserves and Surplus | 0.36 | 2.06 | 3.31 | 4.22 | 5.79 | |
| Total Shareholders Funds | 3.36 | 5.07 | 6.31 | 7.22 | 8.80 | |
| NON-CURRENT LIABILITIES | ||||||
| Long Term Borrowings | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Deferred Tax Liabilities [Net] | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Long Term Liabilities | 7.71 | 2.90 | 0.08 | 0.17 | 0.05 | |
| Long Term Provisions | 0.09 | 0.12 | 0.10 | 0.08 | 0.13 | |
| Total Non-Current Liabilities | 7.80 | 3.02 | 0.17 | 0.24 | 0.18 | |
| CURRENT LIABILITIES | ||||||
| Short Term Borrowings | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Trade Payables | 8.24 | 5.67 | 6.47 | 4.05 | 2.66 | |
| Other Current Liabilities | 1.01 | 0.75 | 1.50 | 2.18 | 2.15 | |
| Short Term Provisions | 0.08 | 0.08 | 0.08 | 0.09 | 0.09 | |
| Total Current Liabilities | 9.33 | 6.51 | 8.05 | 6.32 | 4.90 | |
| Total Capital And Liabilities | 20.49 | 14.59 | 14.53 | 13.78 | 13.87 | |
| ASSETS | ||||||
| NON-CURRENT ASSETS | ||||||
| Tangible Assets | 0.46 | 0.33 | 0.37 | 0.39 | 0.14 | |
| Intangible Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Capital Work-In-Progress | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Fixed Assets | 0.46 | 0.33 | 0.37 | 0.39 | 0.14 | |
| Non-Current Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Deferred Tax Assets [Net] | 0.51 | 0.46 | 0.00 | 0.00 | 0.15 | |
| Long Term Loans And Advances | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Non-Current Assets | 2.01 | 0.66 | 0.76 | 1.21 | 0.86 | |
| Total Non-Current Assets | 2.99 | 1.45 | 1.13 | 1.60 | 1.15 | |
| CURRENT ASSETS | ||||||
| Current Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Inventories | 10.47 | 6.02 | 4.79 | 4.72 | 0.26 | |
| Trade Receivables | 3.41 | 3.88 | 5.32 | 2.81 | 9.28 | |
| Cash And Cash Equivalents | 0.20 | 0.40 | 0.44 | 0.22 | 0.40 | |
| Short Term Loans And Advances | 0.02 | 0.02 | 0.02 | 0.01 | 0.01 | |
| OtherCurrentAssets | 3.40 | 2.82 | 2.84 | 4.42 | 2.78 | |
| Total Current Assets | 17.50 | 13.14 | 13.40 | 12.19 | 12.73 | |
| Total Assets | 20.49 | 14.59 | 14.53 | 13.78 | 13.87 | |
| OTHER ADDITIONAL INFORMATION | ||||||
| CONTINGENT LIABILITIES, COMMITMENTS | ||||||
| Contingent Liabilities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| CIF VALUE OF IMPORTS | ||||||
| Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Stores, Spares And Loose Tools | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Trade/Other Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Capital Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| EXPENDITURE IN FOREIGN EXCHANGE | ||||||
| Expenditure In Foreign Currency | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| REMITTANCES IN FOREIGN CURRENCIES FOR DIVIDENDS | ||||||
| Dividend Remittance In Foreign Currency | -- | -- | -- | -- | -- | |
| EARNINGS IN FOREIGN EXCHANGE | ||||||
| FOB Value Of Goods | -- | -- | -- | 0.00 | 31.93 | |
| Other Earnings | -- | -- | -- | -- | -- | |
| BONUS DETAILS | ||||||
| Bonus Equity Share Capital | -- | -- | -- | -- | -- | |
| NON-CURRENT INVESTMENTS | ||||||
| Non-Current Investments Quoted Market Value | -- | -- | -- | -- | -- | |
| Non-Current Investments Unquoted Book Value | -- | -- | -- | -- | -- | |
| CURRENT INVESTMENTS | ||||||
| Current Investments Quoted Market Value | -- | -- | -- | -- | -- | |
| Current Investments Unquoted Book Value | -- | -- | -- | -- | -- |
24.11.2025
Brawn Pharma Standalone September 2025 Net Sales at Rs 4.89 crore, up 48.36% Y-o-Y
28.05.2025
Brawn Pharma Standalone March 2025 Net Sales at Rs 2.26 crore, down 34.45% Y-o-Y
17.02.2025
Brawn Pharma Standalone December 2024 Net Sales at Rs 3.84 crore, up 35.25% Y-o-Y
25.11.2024
Brawn Pharma Standalone September 2024 Net Sales at Rs 3.30 crore, up 12.95% Y-o-Y
24.11.2025
Brawn Pharma Standalone September 2025 Net Sales at Rs 4.89 crore, up 48.36% Y-o-Y
28.05.2025
Brawn Pharma Standalone March 2025 Net Sales at Rs 2.26 crore, down 34.45% Y-o-Y
17.02.2025
Brawn Pharma Standalone December 2024 Net Sales at Rs 3.84 crore, up 35.25% Y-o-Y
25.11.2024
Brawn Pharma Standalone September 2024 Net Sales at Rs 3.30 crore, up 12.95% Y-o-Y
02.04.2026
02.04.2026
Lupin shares down 2% as arm to acquire 43.38% stake in Multicare Pharma
02.04.2026
02.04.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth